Author

H. Wajant

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

C. Guillonneau· 1 shared C. Serazin· 1 shared D.-J. Wendering· 1 shared F. Heinrich· 1 shared G. M. Guerra· 1 shared H.-D. Volk· 1 shared I. Anegon· 1 shared J. Knop· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

C. Guillonneau

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Single cell analysis reveals CD45RClow/-TNFR2+CD29lowCD8+ Tregs with superior activity

C. Serazin, L. Flippe, M. Streitz, D.-J. Wendering, S. Schlickeiser, F. Heinrich, P. Durek, G. M. Guerra, K. Lehmann, M.-F. Mashreghi, H. Wajant, H.-D. Volk, I. Anegon, L. David, S. Bezie, C. Guillonneau

The paper identifies and characterizes three subsets of human CD8+ regulatory T cells using single-cell CITE-seq and VDJ sequencing, highlighting a subset with superior suppressive activity.

bioRxiv · Dec 13, 2023 · PreprintImmunology

TNFR2 induced priming of NLRP3-inflammasome via RIPK1 leads to pyroptosis in XIAP deficient cells

J. Knop, L. M. Spilgies, S. Rufli, R. Reinhardt, L. Vasilikos, M. Yabal, P. J. Jost, H. Wajant, M. D. Robinson, T. Kaufmann, W. W.-L. Wong

The paper shows TNFR2 activation in XIAP-deficient cells leads to NLRP3 inflammasome priming and pyroptosis via RIPK1 and ROS, with implications for reducing IL-18 release in XLP-2 patients.

bioRxiv · Feb 15, 2019Immunology